Ir-CPI (BIOX-101) is a novel therapeutic agent derived from a natural protein found in the salivary glands of the tick Ixodes ricinus. This tick has developed a sophisticated mechanism to facilitate feeding on the blood of its host. Ticks must overcome the host's immune defenses and prevent blood clotting to ensure a successful blood meal, and they achieve this by secreting various bioactive substances in their saliva.

Ir-CPI (BIOX-101) displays an antithrombotic activity through its interaction with upstream blood coagulation factors (FXIa/FXIIa) of the intrinsic pathway.

Bioxodes has also demonstrated that Ir-CPI decreases neutrophil activation and Neutrophil Extracellular Trap (NET) release. Neutrophils and NETs, networks of extracellular fibers primarily constituted of DNA, are key components of the neuroinflammatory and thrombotic processes encountered in patients with intracerebral hemorrhage (ICH).

Due to its outstanding dual mechanism of action on both coagulation factors and neutrophils, Ir-CPI not only prevents thromboinflammatory processes but also represents a promising alternative to current anticoagulants as deficiencies in FXII and FXI protect against thrombosis without causing spontaneous hemorrhage.